Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
FDMT 4 D Molecular Therapeutics, Inc.	$351M	$0 100.0% of portfolio	0	Q2 2025 New
ETNB 89bio, Inc.	$690M	$0 100.0% of portfolio	0	Q2 2025 New
AADI Aadi Bioscience, Inc.	$35.9M	$0 100.0% of portfolio	0	Q2 2025 New
ABCL Ab Cellera Biologics Inc.	$1.05B	$0 100.0% of portfolio	0	Q2 2025 New
ABEO Abeona Therapeutics Inc.	$26.5M	$0 100.0% of portfolio	0	Q2 2025 New
ABSI Absci Corp	$266M	$0 100.0% of portfolio	0	Q2 2025 New
ACIU Ac Immune Sa	$276M	$0 100.0% of portfolio	0	Q2 2025 New
ACAD Acadia Pharmaceuticals Inc	$3.89B	$0 100.0% of portfolio	0	Q2 2025 New
ATNM Actinium Pharmaceuticals, Inc.	$32.7M	$0 100.0% of portfolio	0	Q2 2025 New

ABOS Acumen Pharmaceuticals, Inc.	$72.1M	$0 100.0% of portfolio	0	Q2 2025 New
ACXP Acurx Pharmaceuticals, Inc.	$48.8M	$0 100.0% of portfolio	0	Q2 2025 New
ADAG Adagene Inc.	$80.8M	$0 100.0% of portfolio	0	Q2 2025 New
ADGI Adagio Therapeutics, Inc.	$505M	$0 100.0% of portfolio	0	Q2 2025 New
ADAP Adaptimmune Therapeutics PLC	$4.9M	$0 100.0% of portfolio	0	Q2 2025 New
ADPT Adaptive Biotechnologies Corp	$2.01B	$0 100.0% of portfolio	0	Q2 2025 New
ADCT Adc Therapeutics Sa	$307M	$0 100.0% of portfolio	0	Q2 2025 New
ACET Adicet Bio, Inc.	$26.4M	$0 100.0% of portfolio	0	Q2 2025 New
ADMA Adma Biologics, Inc.	$3.06B	$0 100.0% of portfolio	0	Q2 2025 New

AGIO Agios Pharmaceuticals, Inc.	$2.39B	$0 100.0% of portfolio	0	Q2 2025 New
AIKI A Ikido Pharma Inc.	$20.8M	$0 100.0% of portfolio	0	Q2 2025 New
AKBA Akebia Therapeutics, Inc.	$313M	$0 100.0% of portfolio	0	Q2 2025 New
AKRO Akero Therapeutics, Inc.	$2.52B	$0 100.0% of portfolio	0	Q2 2025 New
ALBO Albireo Pharma, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
ALDX Aldeyra Therapeutics, Inc.	$296M	$0 100.0% of portfolio	0	Q2 2025 New
ALEC Alector, Inc.	$102M	$0 100.0% of portfolio	0	Q2 2025 New
ALLR Allarity Therapeutics, Inc.	$12.1M	$0 100.0% of portfolio	0	Q2 2025 New
ALLO Allogene Therapeutics, Inc.	$177M	$0 100.0% of portfolio	0	Q2 2025 New
ALNY Alnylam Pharmaceuticals, Inc.	$55.3B	$0 100.0% of portfolio	0	Q2 2025 New
DRTS Alpha Tau Medical Ltd.	$256M	$0 100.0% of portfolio	0	Q2 2025 New
ATHE Alterity Therapeutics LTD	$154M	$0 100.0% of portfolio	0	Q2 2025 New
ALT Altimmune, Inc.	$204M	$0 100.0% of portfolio	0	Q2 2025 New
ALXO Alx Oncology Holdings Inc	$52.2M	$0 100.0% of portfolio	0	Q2 2025 New
FOLD Amicus Therapeutics, Inc.	$2.66B	$0 100.0% of portfolio	0	Q2 2025 New
AMLX Amylyx Pharmaceuticals, Inc.	$743M	$0 100.0% of portfolio	0	Q2 2025 New
ANTX An2 Therapeutics, Inc.	$22.1M	$0 100.0% of portfolio	0	Q2 2025 New
AVXL Anavex Life Sciences Corp.	$284M	$0 100.0% of portfolio	0	Q2 2025 New
ANEB Anebulo Pharmaceuticals, Inc.	$60.5M	$0 100.0% of portfolio	0	Q2 2025 New
ANIX Anixa Biosciences Inc	$127M	$0 100.0% of portfolio	0	Q2 2025 New
ANNX Annexon, Inc.	$136M	$0 100.0% of portfolio	0	Q2 2025 New
ANVS Annovis Bio, Inc.	$18.9M	$0 100.0% of portfolio	0	Q2 2025 New
APLS Apellis Pharmaceuticals, Inc.	$2.23B	$0 100.0% of portfolio	0	Q2 2025 New
APLT Applied Therapeutics Inc.	$10.6M	$0 100.0% of portfolio	0	Q2 2025 New
APRE Aprea Therapeutics, Inc.	$0	$0 100.0% of portfolio	0	Q2 2025 New
APM Aptorum Group LTD	$18.6M	$0 100.0% of portfolio	0	Q2 2025 New
ABUS Arbutus Biopharma Corp	$678M	$0 100.0% of portfolio	0	Q2 2025 New
ACLX Arcellx, Inc.	$3.94B	$0 100.0% of portfolio	0	Q2 2025 New
ARCT Arcturus Therapeutics Holdings Inc.	$193M	$0 100.0% of portfolio	0	Q2 2025 New
RCUS Arcus Biosciences, Inc.	$1.45B	$0 100.0% of portfolio	0	Q2 2025 New
ARQT Arcutis Biotherapeutics, Inc.	$1.5B	$0 100.0% of portfolio	0	Q2 2025 New
ARDX Ardelyx, Inc.	$908M	$0 100.0% of portfolio	0	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.